<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4242001</article-id><article-id pub-id-type="publisher-id">1470-7330-14-S1-O21</article-id><article-id pub-id-type="doi">10.1186/1470-7330-14-S1-O21</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>Complications following locoregional therapy of renal cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Krokidis</surname><given-names>Miltiadis</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Miltiadis.krokidis@addenbrookes.nhs.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2014</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens AG, Healthcare Sector, Imaging and Therapy Division.</named-content></supplement><fpage>O21</fpage><lpage>O21</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Krokidis; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Krokidis; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/14/S1/O21"/><conference><conf-date>9-11 October 2014</conf-date><conf-name>International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</conf-name><conf-loc>Heidelberg, Germany</conf-loc></conference></article-meta></front><body><sec><title/><p>Renal locoregional therapy or local ablation therapy, offers a valid solution for patients with small renal tumours that are not suitable surgical candidates.</p><p>Local ablation techniques are usually performed under imaging guidance and are minimal invasive. However, complications may occur even with this minimal invasive treatment.</p><p>The most frequent complication of ablation treatment is bleeding. Patients with renal cancer are often on antiplatelet or anticoagulant treatment for other reasons therefore at high risk of bleeding. The formation of a perirenal haematoma is reported in up to 30% from various authors [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Among the ablation methods cryotherapy appears to be leading to the formation of perirenal bleeding, probably due to the fact that a higher number of probes are usually required. Larger scale bleeding that would require transfusion and embolization is less frequent and is reported in up to 2% in various series [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Bleeding in such cases may be taking origin form the intercostal arteries or from the ablation site of the renal parenchyma. Bleeding may also be expressed in the form of haematuria in up to 2.5% of the cases particularly when central lesions are treated [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. However, haematuria may be transitional and urine may clear up after 24-48 hours.</p><p>Further reported complications may be adjacent organ thermal injury, particularly of the colon, that is reported in up to 1% in the various series [<xref ref-type="bibr" rid="B8">8</xref>]. In such cases thermal injury perforation and peritonitis may occur. Hydrodissection with glucose for RFA or CO2 dissection for cryoablation may prevent this complication.</p><p>Furthermore, thermal injury of the renal tract may occur and lead to the formation of a urinoma. Cold solution through an antegrade ureteric stent would protect the ureter from thermal injury when central lesions are treated.</p><p>Pain post treatment may also occur, however it is usually limited within the first two days. If persistent pain occurs then nerve injury needs to be suspected. Infection in up to 2% has been reported [<xref ref-type="bibr" rid="B9">9</xref>] however antibiotics are not routinely administered.</p><p>For the treatment of renal cancer surgical resection remains the standard treatment modality. Locoregional therapy has been frequently used to treat renal cancer in patients not suitable for surgical resection. This approach is minimally invasive, however it is not free of complications that need to be recognized and avoided.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Gervais</surname><given-names>DA</given-names></name><name><surname>Arellano</surname><given-names>RS</given-names></name><name><surname>McGovern</surname><given-names>FJ</given-names></name><name><surname>McDougal</surname><given-names>WS</given-names></name><name><surname>Mueller</surname><given-names>PR</given-names></name><article-title>Radiofrequency ablation of renal cell carcinoma: part 2. Lessons learned with ablation of 100 tumors</article-title><source>AJR</source><year>2005</year><volume>185</volume><issue>1</issue><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.2214/ajr.185.1.01850072</pub-id><pub-id pub-id-type="pmid">15972401</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Breen</surname><given-names>DJ</given-names></name><name><surname>Railton</surname><given-names>NJ</given-names></name><article-title>Minimally invasive treatment of small renal tumors: trends in renal cancer diagnosis and management</article-title><source>Cardiovasc Interv Radiol</source><year>2010</year><volume>33</volume><issue>5</issue><fpage>896</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1007/s00270-010-9892-0</pub-id><pub-id pub-id-type="pmid">20544228</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Varkarakis</surname><given-names>IM</given-names></name><name><surname>Allaf</surname><given-names>ME</given-names></name><name><surname>Inagaki</surname><given-names>T</given-names></name><name><surname>Bhayani</surname><given-names>SB</given-names></name><name><surname>Chan</surname><given-names>DY</given-names></name><name><surname>Su</surname><given-names>L-M</given-names></name><etal/><article-title>Percutaneous radio frequency ablation of renal masses: results at a 2-year mean follow-up</article-title><source>J Urol</source><year>2005</year><volume>174</volume><issue>2</issue><fpage>456</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1097/01.ju.0000165655.91152.c5</pub-id><pub-id pub-id-type="pmid">16006864</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Zagoria</surname><given-names>RJ</given-names></name><name><surname>Traver</surname><given-names>MA</given-names></name><name><surname>Werle</surname><given-names>DM</given-names></name><name><surname>Perini</surname><given-names>M</given-names></name><name><surname>Hayasaka</surname><given-names>S</given-names></name><name><surname>Clark</surname><given-names>PE</given-names></name><article-title>Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas</article-title><source>AJR</source><year>2007</year><volume>189</volume><issue>2</issue><fpage>429</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.2214/AJR.07.2258</pub-id><pub-id pub-id-type="pmid">17646471</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Breen</surname><given-names>DJ</given-names></name><name><surname>Rutherford</surname><given-names>EE</given-names></name><name><surname>Stedman</surname><given-names>B</given-names></name><name><surname>Roy-Choudhury</surname><given-names>SH</given-names></name><name><surname>Cast</surname><given-names>JEI</given-names></name><name><surname>Hayes</surname><given-names>MC</given-names></name><etal/><article-title>Management of renal tumors by image guided radiofrequency ablation: experience in 105 tumors</article-title><source>Cardiovasc Interv Radiol</source><year>2007</year><volume>30</volume><issue>5</issue><fpage>936</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1007/s00270-007-9090-x</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Rhim</surname><given-names>H</given-names></name><name><surname>Dodd</surname><given-names>GD</given-names></name><name><surname>Chintapalli</surname><given-names>KN</given-names></name><name><surname>Wood</surname><given-names>BJ</given-names></name><name><surname>Dupuy</surname><given-names>DE</given-names></name><name><surname>Hvizda</surname><given-names>JL</given-names></name><etal/><article-title>Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications</article-title><source>Radiographics</source><year>2004</year><volume>24</volume><issue>1</issue><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1148/rg.241025144</pub-id><pub-id pub-id-type="pmid">14730035</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>BK</given-names></name><name><surname>Kim</surname><given-names>CK</given-names></name><article-title>Complications of image-guided radiofrequency ablation of renal cell carcinoma: causes, imaging features and prevention methods</article-title><source>Eur Radiol</source><year>2009</year><volume>19</volume><issue>9</issue><fpage>2180</fpage><lpage>2190</lpage><pub-id pub-id-type="doi">10.1007/s00330-009-1399-1</pub-id><pub-id pub-id-type="pmid">19350243</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Rouviere</surname><given-names>O</given-names></name><name><surname>Badet</surname><given-names>L</given-names></name><name><surname>Murat</surname><given-names>FJ</given-names></name><name><surname>Marechal</surname><given-names>JM</given-names></name><name><surname>Colombel</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>X</given-names></name><name><surname>Lyonnet</surname><given-names>D</given-names></name><name><surname>Gelet</surname><given-names>A</given-names></name><article-title>Radiofrequency ablation of renal tumors with an expandable multitined electrode: results, complications, and pilot evaluation of cooled pyeloperfusion for collecting system protection</article-title><source>Cardiovasc Interv Radiol</source><year>2008</year><volume>31</volume><issue>3</issue><fpage>595</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1007/s00270-007-9291-3</pub-id><pub-id pub-id-type="pmid">18247086</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>del Cura</surname><given-names>JL</given-names></name><name><surname>Zabala</surname><given-names>R</given-names></name><name><surname>Iriarte</surname><given-names>JI</given-names></name><name><surname>Unda</surname><given-names>M</given-names></name><article-title>Treatment of renal tumors by percutaneous ultrasound-guided radiofrequency ablation using a multitined electrode: effectiveness and complications</article-title><source>Eur Urol</source><year>2010</year><volume>57</volume><issue>3</issue><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2009.11.025</pub-id><pub-id pub-id-type="pmid">19926208</pub-id></mixed-citation></ref></ref-list></back></article>